Previous 10 | Next 10 |
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) rose 20.3% to $0.0699 on volume of 164,902,840 shares Safe and Green Development Corporation (SGD) rose 36.7% to $0.8477 on volume of 100,466,382 shares PROSHARES TRUST (SQQQ) fell 0.6% to $1...
2024-05-09 13:12:57 ET More on mid-day movers & stocks. SkyWater Earnings Preview: Products In High Demand CareCloud, Inc. (CCLD) Q4 2023 Earnings Call Transcript SkyWater Technology, Inc. 2023 Q4 - Results - Earnings Call Presentation SkyWater Technology...
2024-05-09 11:33:48 ET More on Amgen, CytomX, etc. CytomX Therapeutics, Inc. (CTMX) Q1 2024 Earnings Call Transcript Amgen Could Become A Real Contender In The Obesity Market Amgen's Q1 Earnings: Solid All Court Progress, Major Weight Loss Catalyst Pending Cy...
2024-05-09 10:00:35 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 16 out...
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) rose 22.2% to $0.071 on volume of 95,914,661 shares Pop Culture Group Co. Ltd (CPOP) rose 128.8% to $3.89 on volume of 39,763,492 shares Safe and Green Development Corporation (SGD) rose 40.7...
2024-05-08 21:22:10 ET CytomX Therapeutics, Inc. (CTMX) Q1 2024 Results Conference Call May 08, 2024 05:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chief Executive Officer and Chairman Wayne Chu - Chie...
2024-05-08 17:38:27 ET Gainers: CytomX Therapeutics ( CTMX ) +77% . Tarsus Pharmaceuticals ( TARS ) +15% . ZimVie ( ZIMV ) +13% . Equinix ( EQIX ) +11% . Consensus Cloud Solutions ( CCSI ) +10% . Losers: Cardl...
2024-05-08 16:34:08 ET More on CytomX CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town CytomX Therapeutics, Inc. (CTMX) Q4 2023 Earnings Call Transcript Cyt...
- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051, an EpCAM Targeting PROBODY ® ADC, in solid tumors. Initial data anticipated in...
- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall - - Encouraging initial signs of efficacy observed for CX-904 in advanced pancreatic cancer, including 2 of 6 pat...
News, Short Squeeze, Breakout and More Instantly...
CytomX Therapeutics Inc. Company Name:
CTMX Stock Symbol:
NASDAQ Market:
CytomX Therapeutics Inc. Website:
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a firesid...
SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024. “Chris has mad...